Comparator Data Characteristics and Testing Procedures for the Clinical Performance Evaluation of Continuous Glucose Monitoring Systems.

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes technology & therapeutics Pub Date : 2024-04-01 Epub Date: 2024-02-02 DOI:10.1089/dia.2023.0465
Manuel Eichenlaub, Stefan Pleus, Martina Rothenbühler, Timothy S Bailey, Lia Bally, Ronald Brazg, Daniela Bruttomesso, Peter Diem, Elisabet Eriksson Boija, Marion Fokkert, Cornelia Haug, Rolf Hinzmann, Johan Jendle, David C Klonoff, Julia K Mader, Konstantinos Makris, Othmar Moser, James H Nichols, Kirsten Nørgaard, John Pemberton, Elizabeth Selvin, Loukia Spanou, Andreas Thomas, Nam K Tran, Lilian Witthauer, Robbert J Slingerland, Guido Freckmann
{"title":"Comparator Data Characteristics and Testing Procedures for the Clinical Performance Evaluation of Continuous Glucose Monitoring Systems.","authors":"Manuel Eichenlaub, Stefan Pleus, Martina Rothenbühler, Timothy S Bailey, Lia Bally, Ronald Brazg, Daniela Bruttomesso, Peter Diem, Elisabet Eriksson Boija, Marion Fokkert, Cornelia Haug, Rolf Hinzmann, Johan Jendle, David C Klonoff, Julia K Mader, Konstantinos Makris, Othmar Moser, James H Nichols, Kirsten Nørgaard, John Pemberton, Elizabeth Selvin, Loukia Spanou, Andreas Thomas, Nam K Tran, Lilian Witthauer, Robbert J Slingerland, Guido Freckmann","doi":"10.1089/dia.2023.0465","DOIUrl":null,"url":null,"abstract":"<p><p>Comparing the performance of different continuous glucose monitoring (CGM) systems is challenging due to the lack of comprehensive guidelines for clinical study design. In particular, the absence of concise requirements for the distribution of comparator (reference) blood glucose (BG) concentrations and their rate of change (RoC) that are used to evaluate CGM performance, impairs comparability. For this article, several experts in the field of CGM performance testing have collaborated to propose characteristics of the distribution of comparator measurements that should be collected during CGM performance testing. Specifically, it is proposed that at least 7.5% of comparator BG concentrations are <70 mg/dL (3.9 mmol/L) and >300 mg/dL (16.7 mmol/L), respectively, and that at least 7.5% of BG-RoC combinations indicate fast BG changes with impending hypo- or hyperglycemia, respectively. These proposed characteristics of the comparator data can facilitate the harmonization of testing conditions across different studies and CGM systems and ensure that the most relevant scenarios representing real-life situations are established during performance testing. In addition, a study protocol and testing procedure for the manipulation of glucose levels are suggested that enable the collection of comparator data with these characteristics. This work is an important step toward establishing a future standard for the performance evaluation of CGM systems.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10979680/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2023.0465","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Comparing the performance of different continuous glucose monitoring (CGM) systems is challenging due to the lack of comprehensive guidelines for clinical study design. In particular, the absence of concise requirements for the distribution of comparator (reference) blood glucose (BG) concentrations and their rate of change (RoC) that are used to evaluate CGM performance, impairs comparability. For this article, several experts in the field of CGM performance testing have collaborated to propose characteristics of the distribution of comparator measurements that should be collected during CGM performance testing. Specifically, it is proposed that at least 7.5% of comparator BG concentrations are <70 mg/dL (3.9 mmol/L) and >300 mg/dL (16.7 mmol/L), respectively, and that at least 7.5% of BG-RoC combinations indicate fast BG changes with impending hypo- or hyperglycemia, respectively. These proposed characteristics of the comparator data can facilitate the harmonization of testing conditions across different studies and CGM systems and ensure that the most relevant scenarios representing real-life situations are established during performance testing. In addition, a study protocol and testing procedure for the manipulation of glucose levels are suggested that enable the collection of comparator data with these characteristics. This work is an important step toward establishing a future standard for the performance evaluation of CGM systems.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
连续血糖监测系统临床性能评估的对比数据特征和测试程序。
由于缺乏全面的临床研究设计指南,比较不同连续血糖监测(CGM)系统的性能具有挑战性。特别是,用于评估 CGM 性能的参照血糖 (BG) 浓度及其变化率 (RoC) 的分布缺乏简明的要求,影响了可比性。在本文中,几位 CGM 性能测试领域的专家合作提出了 CGM 性能测试期间应收集的参照物测量值分布特点。具体来说,建议至少有 7.5% 的参照物血糖浓度分别为 300 毫克/分升(16.7 毫摩尔/升),至少有 7.5% 的 BG-RoC 组合分别显示即将出现低血糖或高血糖的快速血糖变化。对比数据的这些拟议特征有助于协调不同研究和 CGM 系统的测试条件,并确保在性能测试期间建立最能代表真实情况的相关场景。此外,还提出了操纵血糖水平的研究方案和测试程序,以便收集具有这些特征的参照数据。这项工作是未来建立 CGM 系统性能评估标准的重要一步。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
期刊最新文献
Safety of Options to "Boost" (Enhancing Insulin Infusion Rates) and "Ease-Off" (Reducing Insulin Infusion Rates) in CamAPS FX Hybrid Closed-Loop System: A Real-World Analysis. Clinical Utility of Serum C-peptide Concentration for Hospitalized Patients with Hyperglycemia. An Automated Insulin Delivery System with Automatic Meal Bolus Based on a Hand-Gesturing Algorithm. Noninvasive Real-Time Glucose Monitoring Is in the Near Future. Accuracy of a Real-Time Continuous Glucose Monitor in Pediatric Diabetic Ketoacidosis Admissions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1